Phase 2b trial results of novel TB regimen show potential to shorten treatment
|
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial. PaMZ is a three-drug regimen: pretomanid (Pa), moxifloxacin (M) and pyrazinamide (Z). The therapy is intended for those patients whose TB infections are sensitive to the three drugs, including people with drug-sensitive and multidrug-resistant TB (MDR-TB).The results of this trial show the potential for the PaMZ regimen to improve treatment for tuberculosis.
|
|
Source :
www.sciencedaily.com
2015/3/30 10:49
|
